Connected Trial Execution: Why Integrating IRT, eCOA And Clinical Supply Matters More Than Ever

When randomization, patient-reported outcomes, and drug supply run as separate systems, clinical trial teams end up reconciling data by hand. This is especially true in oncology and other complex, multinational studies, where it can cause delays, duplicated effort, and reduced visibility when oversight matters most.

This paper examines why IRT, eCOA, and clinical supply work best as one connected operating model rather than as separate procurement categories. Bringing these functions together gives sponsors greater control over trial execution, cuts down on manual reconciliation, and makes studies easier to defend during inspection. We also look at what safe integration requires: strong governance, thorough validation, and disciplined change control, as well as the risks that come with leaning too heavily on a single vendor. As trials grow more complex, closing the gaps between systems offers a practical way to move faster and run more reliable studies with fewer avoidable disruptions.